Related Experiment Video

Updated: Aug 19, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

Matthew M Cooney1, Jose Ortiz, Ronald M Bukowski

  • 1Developmental Therapeutics Program, Case Comprehensive Cancer Center, University Hospitals of Cleveland and Cleveland Clinic Foundation, 11100 Euclid Avenue, BHC-6, Cleveland, OH 44106, USA. matthew.cooney@uhhs.com

Current Oncology Reports
|February 19, 2005
PubMed

Insights

Novel vascular targeting agents (VTAs) disrupt tumor blood supply, leading to cancer cell death via hypoxia. These agents, including biologics and small molecules, show promise in early clinical trials and are being combined with standard therapies.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Tumor growth relies on a blood supply from the vascular endothelium.
  • Targeting tumor vasculature offers a strategy to inhibit cancer progression.

Purpose of the Study:

  • To explore novel anticancer compounds targeting tumor vasculature.
  • To investigate the potential of vascular targeting agents (VTAs) in cancer treatment.

Main Methods:

  • Classification of VTAs into biologic therapies and small molecule compounds.
  • Review of early clinical development and phase I trial data for VTAs.

Main Results:

  • VTAs aim to rapidly shut down tumor blood supply.
  • This leads to tumor death through hypoxia and nutrient deprivation.
  • VTAs have shown clinical activity in phase I trials.

Conclusions:

  • VTAs represent a promising class of anticancer agents.
  • Further evaluation with chemotherapy and radiotherapy is ongoing.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...